iTBS for Increased Appetite Induced by Antipsychotics
Condition(s) studied
Investigational drug(s) / intervention(s)
Active iTBS: Mag-TD
Sham iTBS: Mag-TD
Study summary
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to healthy people. Conventional high-frequency rTMS have been used to treat people with obesity and showed certain effectiveness. However, studies involving schizophrenia patients and intermittent theta burst (iTBS) mode are rarely seen. The goal of this clinical trial is to evaluate the efficacy and safety of iTBS on ameliorating increased appetite induced by antipsychotics in people with schizophrenia.
Eligibility
Primary outcome measure(s)
- Changes in body mass index (BMI) — Baseline, after 5 treatment days, 2 weeks and 4 weeks post-treatment
Weight gain will be assessed by BMI, caculated by weight in kilograms divided by height in meters squared
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Central South University | Changsha | Hunan | Not Yet Recruiting |
| The Second People's Hospital of Dali Bai Autonomous Prefecture | Dali | Yunnan | Recruiting |
More Central South University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05783063 on ClinicalTrials.gov ↗ ← All trials in China